At Therapure Biologics, we’re coupling our biomanufacturing excellence with our extensive knowledge of the plasma proteins industry to modernize the purification and commercialization of plasma protein therapeutics. Our commitment to product quality and patient safety is central to everything we do. That’s why we developed and invested in a transformative technology called PlasmaCap EBA™ to enhance the purification of plasma proteins.
Our research and development team has fine-tuned our PlasmaCap EBA technology and are working diligently on a pipeline of critically important, in-demand, plasma protein therapeutics.
Our initial focus is on three important plasma proteins: intravenous immunoglobulin (IVIG), albumin, and alpha-1 antitrypsin (AAT) which are established products in plasma protein industry with growing demand. Using our extensive knowledge in plasma proteins and working with key industry players, we have developed a program to launch these products to address the needs of the market.
Learn more about individual pipeline products by clicking on the links below:
In addition to targeting these plasma proteins, Therapure Biologics is leveraging its technology to develop other proteins of interest.
- Marketing Research Bureau (2013), “The Worldwide Plasma Proteins Market in 2012”.